Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

T-Cell Lymphomas Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 129 Pages GlobalData March, 2022 GBDT17155704
Best Price Guarantee
Price from $10,995
Length 129 Pages
Publisher GlobalData
Published Date March, 2022
SKU GBDT17155704

T-Cell Lymphomas Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Summary

T-cell lymphomas (TCL) are white blood cell malignancies and a subtype of non-Hodgkin lymphomas (NHL), representing less than 15% of NHL in the US. The most important clinical distinction is made in separating primary cutaneous TCLs (CTCL), which affect primarily the skin, from peripheral TCLs (PTCL), which can be nodal or extranodal. A number of T-cell malignancies present with leukemic characteristics, and due to the focus of this report being on lymphoma, these have been excluded, namely T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, and adult T-cell leukemia/lymphoma. What differs widely is the involvement of hematologic oncologists: in some markets, CTCL is managed exclusively by dermatologists, and in other markets by dermatologists with contribution by a hematologist, or exclusively by hematologists in advanced disease. Given that skin-directed therapy is of dermatologic specialty, it is out of scope for this report and such agents will not be examined individually.

The global market is expected to grow from $956 million in 2020 to $1.82 billion in 2030 at a moderate CAGR of 6.6%. The introduction of 14 new pipeline agents and label expansions for currently approved agents are key drivers of this market growth. However, the market value already shows signs of congestion and there are key patent expiries that will prohibit growth.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 14 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM are key patent expiries of most of the standard of care during the forecast period and a lack of industrial investment for niche patient populations such as CTCL first line patients.
  • Among the late-stage pipeline products and marketed agents, monoclonal antibodies and targeted therapies are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the TCL market include: Better systemic treatments for CTCL, R/R PTCL patients, and a lack of combinational approaches and biomarkers in clinical trials.
KEY QUESTIONS ANSWERED
  • Fourteen late-stage pipeline agents are expected to enter the T-cell lymphoma market from 2020 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in T-cell lymphoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How has the introduction of Adcetris and Poteligeo shaped the relapsed/refractory care? How will the competition fare?
  • What is the expected future uptake of monoclonal antibodies and targeted therapies in TCL across the 8MM?
Scope
  • Overview of T-cell lymphoma including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline T-cell lymphoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting T-cell lymphoma therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
  • Analysis of the current and future market competition in the global T-cell lymphoma therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global T-cell lymphoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T-cell lymphoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global T-cell lymphoma therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 T-Cell Lymphomas: Executive Summary
1.1 The T-Cell Lymphoma Market Will Grow to $1.77B by 2030, at a 6.4% CAGR
1.2 New Target Development and Creating Niche Sub-Markets Within CTCL or PTCL Are Dominant R&D Strategies
1.3 A High Level of Unmet Need Will Remain for Most TCL Subtypes During the Forecast Period
1.4 The Late-Stage Pipeline in T-Cell Lymphoma Is Rich, Albeit Unlikely to Provide Clinical Benefit of a Large Magnitude
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for T-Cell Lymphomas
4.5.1 Diagnosed Incident Cases of TCL
4.5.2 Age-Specific Diagnosed Incident Cases of TCL
4.5.3 Sex-Specific Diagnosed Incident Cases of TCL
4.5.4 Diagnosed Incident Cases of TCL by Subtype
4.5.5 Diagnosed Incident Cases of TCL by Stage at Diagnosis
4.5.6 Diagnosed Incident Cases of TCL by CD30 Expression
4.5.7 Five-Year Diagnosed Prevalent Cases of TCL
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
5.2.1 Diagnosis
5.2.2 Early-Stage Treatment
5.2.3 Systemic Therapy
5.2.4 Transplant
5.2.5 Relapsed/Refractory
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Better Systemic Treatments for CTCL
7.3 Primarily Refractory and Relapsed PTCL Patients
7.4 Combinational Approaches in Clinical Trials
7.5 Maintenance Regimens for PTCL Patients in Remission
7.6 Clinical Trials for Biomarker-Driven Agents to Capitalize on Validated Targets
8 R&D Strategies
8.1 Overview
8.1.1 Serving Underserved Markets with Proven Mechanisms of Action
8.1.2 Subtype-Specific Drug Launches
8.1.3 Focus on Novel Targets
8.2 Clinical Trials Design
8.2.1 Rarity of the Disease
8.2.2 More Flexible Inclusion/Exclusion Criteria in Clinical Trials Are Required
8.2.3 Primary and Secondary Endpoints
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers – Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 China
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix
List of Tables
Table 1: T-Cell Lymphomas: Key Metrics in the 8MM
Table 2: Subtype Classification and Staging Systems Used for T-Cell Lymphomas
Table 3: Risk Factors and Comorbidities for TCL
Table 4: Treatment Guidelines for T-Cell Lymphomas
Table 5: Key Pivotal T-Cell Lymphoma Clinical Trials with Their Clinical Outcomes
Table 6: Top 10 Deals by Value, 2016–21
Table 7: T-Cell Lymphomas Market – Global Drivers and Barriers, 2020–30
Table 8: Key Events Impacting Sales for T-Cell Lymphomas in the US, 2020–30
Table 9: T-Cell Lymphomas Market – Drivers and Barriers in the US, 2020–30
Table 10: Key Events Impacting Sales for T-Cell Lymphomas in the 5EU, 2020–30
Table 11: T-Cell Lymphomas Market – Drivers and Barriers in the 5EU, 2020–30
Table 12: Key Events Impacting Sales for T-Cell Lymphomas in Japan, 2020–30
Table 13: T-Cell Lymphomas Market – Drivers and Barriers in Japan, 2020–30
Table 14: Key Events Impacting Sales for T-Cell Lymphomas in China, 2020–30
Table 15: T-Cell Lymphomas Market – Drivers and Barriers in China, 2020–30
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for T-Cell Lymphomas in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in T-Cell Lymphomas During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Biologic Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of T-Cell Lymphomas During the Forecast Period
Figure 4: Competitive Assessment of the Late-Stage Small Molecule Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of T-Cell Lymphomas During the Forecast Period
Figure 5: Key Therapeutic Targets in TCL
Figure 6: 8MM, Diagnosed Incidence of TCL, Men and Women, Cases per 100,000 Population, All Ages, 2010 and 2020
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL
Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of TCL by Subtype
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL By Stage at Diagnosis
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL by CD30 Expression
Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of TCL
Figure 12: 8MM, Diagnosed Incident Cases of TCL, N, Both Sexes, All Ages, 2020
Figure 13: 8MM, Diagnosed Incident Cases of TCL by Age, N, Both Sexes, 2020
Figure 14: 8MM, Diagnosed Incident Cases of TCL by Sex, N, All Ages, 2020
Figure 15: 8MM, Diagnosed Incident Cases Proportion of TCL (CTCL and PTCL) by Subtype, %, Both Sexes, All Ages, 2020
Figure 16: 8MM, Diagnosed Incident Cases Proportions of MF and SS by Stage at Diagnosis, %, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Incident Cases Proportion of Primary Cutaneous ALCL and Others by Stage at Diagnosis, %, Both Sexes, All Ages, 2020
Figure 18: 8MM, Diagnosed Incident Cases Proportion of PTCL by Stage at Diagnosis, %, Both Sexes, All Ages, 2020
Figure 19: 8MM, Diagnosed Incident Cases Proportion of TCL with CD30 Expression, %, Both Sexes, All Ages, 2020
Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of TCL, N, Both Sexes, All Ages, 2020
Figure 21: Treatment Algorithm in Cutaneous TCL
Figure 22: Treatment Algorithm in Peripheral TCL
Figure 23: Unmet Needs and Opportunities in T-Cell Lymphomas
Figure 24: Overview of the Development Pipeline in T-Cell Lymphomas
Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for T-Cell Lymphomas in the 8MM During the Forecast Period
Figure 26: Competitive Assessment of the Marketed and Pipeline Small Molecule Inhibitors and Chemotherapies Benchmarked Against the Standard of Care, HDAC inhibitors (i.e., Istodax)
Figure 27: Competitive Assessment of the Marketed and Pipeline Targeted Monoclonal Antibodies and Immune Checkpoint Inhibitors Benchmarked Against the Standard of Care, Adcetris
Figure 28: Analysis of the Company Portfolio Gap in T-Cell Lymphomas During the Forecast Period
Figure 29: Global (8MM) Sales Forecast by Country for T-Cell Lymphomas in 2020 and 2030
Figure 30: Sales Forecast by Class for T-Cell Lymphomas in the US in 2020 and 2030
Figure 31: Sales Forecast by Class for T-Cell Lymphomas in the 5EU in 2020 and 2030
Figure 32: Sales Forecast by Class for T-Cell Lymphomas in Japan in 2020 and 2030
Figure 33: Sales Forecast by Class for T-Cell Lymphomas in China in 2020 and 2030

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings